SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

Travere Therapeutics Is Maintained at Buy by Guggenheim

Ratings actions from Benzinga: GMT) Travere Therapeutics Price Target Raised to $89.00/Share From $75.00 by GuggenheimRatings actions from Benzinga

TVTX

Related stories